GlassScriptPhysician profile
Larry Weckesser
NPI 1124542006
$10,355.63
in general payments reported to CMS, 2019-2025
32 companies · $3,436 in 2025
The $3,436 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,341 · 2022: $1,749 · 2023: $1,492 · 2024: $2,339 · 2025: $3,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,041 · Travel and Lodging: $1,215 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,040.56 |
| Travel and Lodging | $1,214.69 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,960.30 | 2021-2025 | Minimed 780g, Inceptiv |
| Lilly USA, LLC | $1,479.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $759.59 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $720.98 | 2021-2025 | Evenity, Tepezza, Repatha |
| Corcept Therapeutics | $563.21 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $493.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $469.42 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.85 | 2021-2025 | Jardiance |
| Abbott Laboratories | $439.19 | 2021-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $420.50 | 2021-2025 | Tirosint, Tirosint, Licart |
| Abbvie INC. | $344.14 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $317.01 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $274.01 | 2021-2024 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $272.81 | 2022-2025 | Strensiq |
| Esperion Therapeutics, INC. | $198.51 | 2024-2025 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $160.28 | 2021-2023 | |
| Avvisto Therapeutics, LLC | $147.72 | 2024-2025 | Cycloset |
| Dexcom, INC. | $142.92 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $103.97 | 2021-2023 | Steglatro, Steglujan, Segluromet |
| Insulet Corporation | $103.67 | 2022-2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.67 | 2021-2023 | Cycloset |
| Amarin Pharma, INC. | $72.75 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $72.75 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $58.91 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $55.10 | 2025 | Twiist |
| Beta Bionics, INC. | $45.94 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Recordati_rare_diseases_inc. | $34.22 | 2021-2025 | Isturisa |
| Radius Health, INC. | $33.55 | 2024-2025 | Tymlos |
| Nevro Corp. | $23.85 | 2024 | Senza |
| Averitas Pharma INC. | $19.27 | 2025 | Qutenza |
| Zealand Pharma US, INC. | $13.97 | 2022 | |
| Clarus Therapeutics INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Weckesser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.